Kevin Koch, Ph.D., is a seasoned biotechnology CEO, venture partner, company founder, and board member with extensive experience in drug discovery and development. They founded and served as President and Chief Scientific Officer of a public biotechnology company that developed 21 INDs over 12 years and successfully raised over $500 million in public financing. Previously, Koch held senior leadership roles at Biogen and Pfizer, overseeing various drug discovery platforms and collaborations. Currently, they lead Edgewise Therapeutics, focusing on therapeutics for muscle diseases and serious cardiac conditions, while also serving as a Venture Partner at OrbiMed. Koch holds a Ph.D. in Synthetic Organic Chemistry from the University of Rochester.
This person is not in the org chart
This person is not in any teams
This person is not in any offices